Plenter Robert J, Grazia Todd J, Nelson David P, Zamora Martin R, Gill Ronald G, Pietra Biagio A
Department of Surgery, Colorado Center for Transplantation Care, Research and Education, University of Colorado Denver, 1775 Aurora Ct., Aurora, CO 80045, USA; Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, 12631 E. 17th Ave, Aurora, CO 80045, USA.
Department of Pediatrics, Cincinnati Children's Hospital, 3333 Burnet Ave, Cincinnati, OH 45229, USA.
Cell Immunol. 2015 Jan;293(1):30-3. doi: 10.1016/j.cellimm.2014.11.007. Epub 2014 Dec 6.
Fas Ligand limits inflammatory injury and permits allograft survival by inducing apoptosis of Fas-bearing lymphocytes. Previous studies have shown that the CD4(+) T-cell is both sufficient and required for murine cardiac allograft rejection. Here, utilizing a transgenic mouse that over-expresses Fas Ligand specifically on cardiomyocytes as heart donors, we sought to determine if Fas Ligand on graft parenchymal cells could resist CD4(+) T-cell mediated rejection. When transplanted into fully immunocompetent BALB/c recipients Fas Ligand transgenic hearts were acutely rejected. However, when transplanted into CD4(+) T-cell reconstituted BALB/c-rag(-/-) recipients, Fas Ligand hearts demonstrated long-term survival. These results indicate that Fas Ligand over-expression on cardiomyocytes can indeed resist CD4(+) T-cell mediated cardiac rejection and suggests contact dependence between Fas Ligand expressing graft parenchymal cells and the effector CD4(+) T-cells.
Fas配体通过诱导携带Fas的淋巴细胞凋亡来限制炎症损伤并使同种异体移植存活。先前的研究表明,CD4(+) T细胞对于小鼠心脏同种异体移植排斥反应既是充分的也是必需的。在此,利用一种在心肌细胞上特异性过表达Fas配体的转基因小鼠作为心脏供体,我们试图确定移植实质细胞上的Fas配体是否能够抵抗CD4(+) T细胞介导的排斥反应。当移植到具有完全免疫活性的BALB/c受体中时,Fas配体转基因心脏被急性排斥。然而,当移植到CD4(+) T细胞重建的BALB/c-rag(-/-)受体中时,Fas配体心脏表现出长期存活。这些结果表明,心肌细胞上Fas配体的过表达确实可以抵抗CD4(+) T细胞介导的心脏排斥反应,并提示表达Fas配体的移植实质细胞与效应CD4(+) T细胞之间存在接触依赖性。